

# Cross-Sectional Survey of Rheumatologists and Dermatologists to Assess the Effectiveness of the Baricitinib Additional Risk Minimization Measures in Canada

**First published:** 14/01/2025

**Last updated:** 13/02/2025

Study

Planned

## Administrative details

### EU PAS number

EUPAS1000000438

---

### Study ID

1000000438

---

### DARWIN EU® study

No

---

### Study countries

 Canada

---

### Study description

Survey study of HCPs to assess effectiveness of aRMM.

---

## Study status

Planned

## Research institutions and networks

### Institutions

#### YOLARX Consultants

 France

**First published:** 30/07/2018

**Last updated:** 06/03/2024

**Institution**

**Non-Pharmaceutical company**

**ENCePP partner**

## Contact details

### Study institution contact

Kristin Meyers [meyers\\_kristin\\_joy@lilly.com](mailto:meyers_kristin_joy@lilly.com)

**Study contact**

[meyers\\_kristin\\_joy@lilly.com](mailto:meyers_kristin_joy@lilly.com)

### Primary lead investigator

Philippe Assad

**Primary lead investigator**

# Study timelines

## **Date when funding contract was signed**

Planned: 24/09/2024

Actual: 23/07/2024

---

## **Study start date**

Planned: 03/02/2025

---

## **Date of final study report**

Planned: 01/04/2026

# Sources of funding

- Pharmaceutical company and other private sector

# More details on funding

Eli Lilly and Company

# Study protocol

[LY3009104 B042 NI Canada Protocol Version 1.pdf](#) (754.47 KB)

# Regulatory

## **Was the study required by a regulatory body?**

Yes

---

## **Is the study required by a Risk Management Plan (RMP)?**

Non-EU RMP only

# Other study registration identification numbers and links

I4V-CA-B042

## Methodological aspects

### Study type

#### Study type list

**Study type:**

Non-interventional study

---

**Scope of the study:**

Assessment of risk minimisation measure implementation or effectiveness

**Data collection methods:**

Primary data collection

---

## Study drug and medical condition

**Medicinal product name**

OLUMIANT

---

**Medicinal product name, other**

baricitinib

## Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

## Use of a Common Data Model (CDM)

### **CDM mapping**

No

## Data quality specifications

### **Check conformance**

Unknown

---

### **Check completeness**

Unknown

---

### **Check stability**

Unknown

---

### **Check logical consistency**

Unknown

## Data characterisation

### **Data characterisation conducted**

No